Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJack A. Khattar - President and CEOPeter Vozzo - Managing DirectorTim Dec - CFONone - Company RepresentativeConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystJon Cox - AnalystKristen Kluska - AnalystPavan Patel - Biopharma Equity Research AnalystStacy Ku - AnalystOperatorGood afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsJack A. Khattar - President and CEOPeter Vozzo - Managing DirectorTim Dec - CFONone - Company RepresentativeConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystJon Cox - AnalystKristen Kluska - AnalystPavan Patel - Biopharma Equity Research AnalystStacy Ku - AnalystOperatorGood afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 ...

Supernus Pharmaceuticals (NasdaqGM:SUPN) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker5Good afternoon. Welcome to Supernus Pharmaceuticals for the quarter and full year 2025 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference is being recorded. I would now like to hand the conference over to Peter Vozzo of ICR Healthcare, Investor Re ...

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ...

Core Insights - Supernus Pharmaceuticals, Inc. is actively participating in multiple investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders in the biopharmaceutical sector [1][2][3]. Conference Participation - The company will attend the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with a fireside chat scheduled for 2:30 p.m. ET in Boston, Massachusetts [1]. - Supernus will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, held in Miami Beach, Florida [2]. - Additionally, the company is set to present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, with a fireside chat at 2:00 p.m. ET in Miami Beach, Florida [3]. Webcast Availability - Live audio webcasts of the TD Cowen and Barclays Conference presentations will be accessible on the Supernus Pharmaceuticals website, with archived replays available for 60 days post-conference [4]. Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, indicating a specialized niche within the biopharmaceutical industry [5]. - The company's neuroscience portfolio includes approved treatments for various conditions such as ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, and migraine, among others [6].

ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-35518 | 20-2590184 | | --- | --- | --- | | (State or other jurisdiction of incorporation | | (I.R.S. Employer Identification No.) | | or organization) | (Commission File Numb ...

Core Insights - Lunai Bioworks has successfully completed its AI platform, which is now commercial and poised for partnerships with pharmaceutical companies, leveraging a closed-loop AI system that enhances drug discovery efficiency and reduces costs [1][2] Group 1: AI Drug Discovery - The AI Drug Discovery engine aims to shorten drug discovery timelines from over 2 years to under 1 year, significantly reducing costs and increasing success rates [2] - Lunai's approach focuses on understanding disease biology and designing better clinical trials, particularly for CNS diseases and oncology, by identifying biologically defined patient subgroups [3][6] - The company has validated its methods through collaborations, such as with Northwell Health and J&J, demonstrating the effectiveness of analyzing large clinical datasets to identify patient subgroups that benefit from specific treatments [3][5] Group 2: AI Bio-Defense Discoveries - Lunai's AI Bio-Defense initiative utilizes its technology to detect emerging chemical and biological threats, aiming to identify effective antidotes and countermeasures [4][10] - The biodefense platform supports the full lifecycle of threat management, including prevention, rapid assessment, and countermeasure identification [10][11] - The company is actively negotiating government contracts to monetize its biodefense program, emphasizing the urgency and national security relevance of its work [12] Group 3: Immunotherapy Developments - Lunai's next-generation allogeneic dendritic cell immunotherapy has shown promising results in preclinical models, achieving complete regression of pancreatic tumors [5] - The company is in discussions for licensing this therapy and other parts of its oncology platform, indicating potential for future revenue streams [5] Group 4: Future Focus and Milestones - Lunai is focused on advancing commercial discussions in clinical data analytics, precision trial design, and biology-driven discoveries [18] - The company aims to finalize funding conversations for its biodefense initiatives and establish a roadmap for its Sentinel, Pathfinder, and CounterAct programs [18] - A significant new pharma royalty partnership program for in-house immunotherapy technologies is also in the works, highlighting the company's commitment to creating shareholder value [18]

Core Insights - Supernus Pharmaceuticals (SUPN) is a commercial-stage pharmaceutical company that has shown significant stock performance, with an increase of over 65% in the last five years and over 335% in the last ten years [1] Company Overview - Supernus is recognized for its strong investment potential in the biotech and pharmaceutical sectors, attracting both novice and experienced investors [1] - The company is part of a broader investment group, Haggerston BioHealth, which provides insights into market trends, catalysts, and financial forecasts for major pharmaceutical companies [1] Investment Analysis - The investment group offers detailed reports on over 1,000 companies, including product sales forecasts and integrated financial statements, which are valuable for making informed investment decisions [1] - The group emphasizes the importance of understanding key trends and catalysts that drive valuations in the biotech, pharma, and healthcare industries [1]

Group 1 - Aristotle Capital Boston, LLC reported strong performance in small-cap equities, with the Russell 2000 Index reaching an all-time high since November 2021, driven by a favorable macroeconomic environment [1] - The Small Cap Equity Fund (Class I-2) returned 3.16% in Q3 2025, underperforming the Russell 2000 Index's total return of 12.39% [1] - The fund highlighted Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as a key stock, which saw a one-month return of 8.74% and a 52-week gain of 39.09% [2] Group 2 - Supernus Pharmaceuticals, Inc. is a Maryland-based specialty pharmaceutical company focused on central nervous system diseases, reporting strong quarterly results that exceeded analyst expectations and raised fiscal year 2025 forecasts [3] - The company reported total revenue of $192.1 million in Q3 2025, an increase from $175.7 million in Q3 2024 [4] - Despite its potential, Supernus Pharmaceuticals is not among the top 30 most popular stocks among hedge funds, with 29 hedge fund portfolios holding its stock at the end of Q3 2025, up from 25 in the previous quarter [4]